GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Asset Turnover

Extrawell Pharmaceutical Holdings (HKSE:00858) Asset Turnover : 0.02 (As of Sep. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Extrawell Pharmaceutical Holdings's Revenue for the six months ended in Sep. 2023 was HK$30.14 Mil. Extrawell Pharmaceutical Holdings's Total Assets for the quarter that ended in Sep. 2023 was HK$1,324.94 Mil. Therefore, Extrawell Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Sep. 2023 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. Extrawell Pharmaceutical Holdings's annualized ROE % for the quarter that ended in Sep. 2023 was -40.95%. It is also linked to ROA % through Du Pont Formula. Extrawell Pharmaceutical Holdings's annualized ROA % for the quarter that ended in Sep. 2023 was -35.88%.


Extrawell Pharmaceutical Holdings Asset Turnover Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Asset Turnover Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.06 0.07 0.06 0.05

Extrawell Pharmaceutical Holdings Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.03 0.03 0.02

Competitive Comparison of Extrawell Pharmaceutical Holdings's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Asset Turnover falls into.



Extrawell Pharmaceutical Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Extrawell Pharmaceutical Holdings's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=72.577/( (1317.101+1444.874)/ 2 )
=72.577/1380.9875
=0.05

Extrawell Pharmaceutical Holdings's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Mar. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=30.141/( (1444.874+1204.998)/ 2 )
=30.141/1324.936
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Extrawell Pharmaceutical Holdings  (HKSE:00858) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Extrawell Pharmaceutical Holdings's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-475.45/1161.1225
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-475.45 / 60.282)*(60.282 / 1324.936)*(1324.936/ 1161.1225)
=Net Margin %*Asset Turnover*Equity Multiplier
=-788.71 %*0.0455*1.1411
=ROA %*Equity Multiplier
=-35.88 %*1.1411
=-40.95 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Extrawell Pharmaceutical Holdings's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-475.45/1324.936
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-475.45 / 60.282)*(60.282 / 1324.936)
=Net Margin %*Asset Turnover
=-788.71 %*0.0455
=-35.88 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Extrawell Pharmaceutical Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines